Currently, the open-label randomized REPLACE-RV study aims to prospectively evaluate the risk for major adverse cardiovascular events in patients with prostate cancer treated with the GnRH antagonist relugolix compared to the GnRH agonist leuprolide acetate. This evidence concerns the gene GNRH1 and Familial prostate cancer.